| PRODUCT NAME | HOLDER | STATUS | DATE | INDICATION |
|---|---|---|---|---|
| Imatinib Teva | Teva B.V. | Authorised | 07/01/2013 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Le… |
| Glivec | Novartis Europharm Limited | Authorised | 07/11/2001 | Precursor Cell Lymphoblastic Leukemia-Lymphoma;Gastrointestinal Stromal Tumors;D… |
| Imatinib Accord | Accord Healthcare S.L.U. | Authorised | 30/06/2013 | Precursor Cell Lymphoblastic Leukemia-Lymphoma;Dermatofibrosarcoma;Myelodysplast… |
| Imatinib Koanaa | Koanaa Healthcare GmbH | Withdrawn | 22/09/2021 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Le… |
| Imatinib Actavis | Actavis Group PTC ehf | Withdrawn | 17/04/2013 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Le… |
| Imatinib medac | Medac | Withdrawn | 25/09/2013 | Precursor Cell Lymphoblastic Leukemia-Lymphoma;Dermatofibrosarcoma;Leukemia, Mye… |
| Imatinib Teva B.V. | Teva B.V. | Withdrawn | 15/11/2017 | Dermatofibrosarcoma;Gastrointestinal Stromal Tumors;Leukemia, Myelogenous, Chron… |
| Ruvise | Novartis Europharm Ltd | Application withdrawn | — |